These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17716416)

  • 41. NICE is dead; long live NICE.
    Chinthapalli K
    BMJ; 2013 Apr; 346():f2546. PubMed ID: 23615594
    [No Abstract]   [Full Text] [Related]  

  • 42. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?
    Sculpher M
    Pharmacoeconomics; 2008; 26(9):721-4. PubMed ID: 18767891
    [No Abstract]   [Full Text] [Related]  

  • 44. Identifying and selecting new procedures for health technology assessment: a decade of nice experience in the United Kingdom.
    Campbell B; Morris R; Mandava L; Murthy L; Gallo H; Ong KJ; Latif A; Patrick H
    Int J Technol Assess Health Care; 2014 Oct; 30(4):454-60. PubMed ID: 25412656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public funding of new cancer drugs: Is NICE getting nastier?
    Mason AR; Drummond MF
    Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A national technology assessment institute.
    Howell A
    Healthplan; 2003; 44(5):40-5. PubMed ID: 14556611
    [No Abstract]   [Full Text] [Related]  

  • 47. The HSJ interview: Andrew Dillon. The NICE guy. Interview by Lyn Whitfield.
    Dillon A
    Health Serv J; 2003 Jun; 113(5858):20-1. PubMed ID: 12808869
    [No Abstract]   [Full Text] [Related]  

  • 48. Evidence and values: paying for end-of-life drugs in the British NHS.
    Chalkidou K
    Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of health economics in the evaluation of surgery and operative technologies.
    Taylor M
    Surgery; 2017 Feb; 161(2):300-304. PubMed ID: 28096035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence and quality, practicalities and judgments: some experience from NICE.
    Culyer A; Rawlins M
    Healthc Q; 2012; 15 Spec No():66-9. PubMed ID: 24863122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
    Hale G; Morris J; Barker-Yip J
    J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
    [No Abstract]   [Full Text] [Related]  

  • 52. Association of study type, sample size, and follow-up length with type of recommendation produced by the National Institute for Health and Clinical Excellence Interventional Procedures Programme.
    Campbell WB; Barnes SJ; Kirby RA; Willett SL; Wortley S; Lyratzopoulos G
    Int J Technol Assess Health Care; 2007; 23(1):101-7. PubMed ID: 17234023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NICE system...shame about the side-effects.
    McVie G
    Lancet Oncol; 2003 Apr; 4(4):203. PubMed ID: 12681259
    [No Abstract]   [Full Text] [Related]  

  • 55. ABPI call for NICE guidance to be made mandatory.
    Tiner R
    Lancet Oncol; 2003 Apr; 4(4):203-4. PubMed ID: 12681260
    [No Abstract]   [Full Text] [Related]  

  • 56. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
    J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NICE work--providing guidance to the British National Health Service.
    Rawlins MD
    N Engl J Med; 2004 Sep; 351(14):1383-5. PubMed ID: 15459297
    [No Abstract]   [Full Text] [Related]  

  • 58. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Economic health technology assessment: challenges and perspectives].
    Zerda A
    Biomedica; 2014; 34(2):161-3. PubMed ID: 24967920
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.